April 15th 2025
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.
In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.
Read More
Addressing Financial Toxicity With Patients and Health Systems
July 23rd 2021Speakers at the Advanced Topics for Oncology Pharmacy Professionals Summit discussed financial toxicity in health care, how it particularly impacts patients with cancer, and how to address the issue with patients and the health system.
Read More
Reduced Medical Spending Associated With Integrated Pharmacy Benefits
Members covered by an integrated pharmacy benefit (as opposed to a pharmacy carve-out) experienced slower growth in medical spending.
Read More
In Most of the US, Self-insured Employers Lack Power at the Bargaining Table With Hospitals
July 20th 2021In this episode of Managed Care Cast, the lead author of an article in the July issue of The American Journal of Managed Care describes the latest research that looks at the power of self-insured employers to negotiate hospital prices and the relationship between employer market power and hospital prices.
Listen
MA Primary Care Payment Models Influenced Telemedicine Usage During the Pandemic, Research Shows
July 16th 2021Larger primary care practices in downside risk–only payment models and capitation saw the highest telemedicine utilization rates by their patients enrolled in Medicare Advantage (MA) plans.
Read More
How Biogen’s Aduhelm Approval Marks a Precipitous Turning Point for the FDA
July 14th 2021A string of controversies surrounding the approval of Biogen's Alzheimer disease drug aducanumab (Aduhelm) has not only called into question the independent nature of the FDA, but puts both providers and patients in a challenging position when it comes to deciding whether or not to prescribe or take the treatment.
Read More
Large Self-insured Employers Lack Power to Effectively Negotiate Hospital Prices
This study examines the ability of self-insured employers to negotiate hospital prices and the relationship between hospital prices and employer market power in the United States.
Read More
Pooled Results From Atezolizumab Trials Show Immune-Related AEs Can Predict Longer OS
July 5th 2021Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.
Read More
CMS Targets Health Care Disparities in ESRD Rulemaking for 2022
July 2nd 2021The proposed changes to the payment model for end stage renal disease (ESRD) would make it the first payment model under the CMS Innovation Center to directly address health equity by incentivizing increased rates of home dialysis and kidney transplants.
Read More
Reports Highlight Strengthening Primary Care After the Pandemic
June 29th 2021Linda Schwimmer, JD, president and CEO of the New Jersey Health Care Quality Institute, discusses 2 reports on strengthening primary care after the COVID-19 pandemic: one from her own organization and the other from the National Academy of Medicine.
Listen
Use of Evidence and Technology to Improve Quality and Eliminate Low-Value Care
June 23rd 2021One-third of health care in the United States is wasted. Despite this recognition, solutions are sparse. The Optimal Care model combines evidence-based medicine, patient-centered technology, and outcomes reporting to transform health care.
Read More
MedPAC to Congress: Change MA Benchmarks, Slow Down on APMs
June 18th 2021The Medicare Payment Advisory Commission (MedPAC) suggested several changes to Medicare Advantage (MA) plan benchmark calculations, with the intent to generate yield savings for Medicare, and urged CMS to streamline alternative payment model (APMs) where it can.
Read More
Commercial and Medicare Advantage Payment for Anesthesiology Services
June 16th 2021Mean in-network commercial allowed amounts and charges per anesthesia conversion factor are 314% and 659% of traditional Medicare rates, respectively. Medicare Advantage payments align with traditional Medicare prices.
Read More
Association of Co-pay Elimination With Medication Adherence and Total Cost
This study evaluated cost and utilization attributed to members enrolled in a health care program with no pharmacy co-pay. Health care savings were identified in addition to medication adherence improvements.
Read More
Who’s Driving the Growth of Medicare Advantage Plans?
June 9th 2021In this episode of Managed Care Cast, we speak with a coauthor of an article in June’s Health Affairs examining the racial and ethnic composition of beneficiaries in Medicare Advantage plans and the potential implications as the program continues to grow.
Listen
ASCO’s Dr Lori Pierce on Equity in Cancer Care: “History Has Its Eyes on Us”
June 5th 2021Equality in cancer care is not sufficient, said Lori Pierce, MD, FASTRO, FASCO, a radiation oncologist from the University of Michigan and president of the American Society of Clinical Oncology (ASCO). Equity—which means that patients have similar outcomes, regardless of circumstance—is harder to achieve.
Read More
Population-Based Return on Investment of Deploying Transient Elastography
Deploying vibration-controlled transient elastography/controlled attenuation parameter devices at the population level is a financially advantageous solution to address the epidemic of fatty liver disease.
Read More